vs

Side-by-side financial comparison of Comstock Holding Companies, Inc. (CHCI) and Organogenesis Holdings Inc. (ORGO). Click either name above to swap in a different company.

Organogenesis Holdings Inc. is the larger business by last-quarter revenue ($37.2M vs $23.9M, roughly 1.6× Comstock Holding Companies, Inc.). On growth, Comstock Holding Companies, Inc. posted the faster year-over-year revenue change (41.5% vs -57.1%). Over the past eight quarters, Comstock Holding Companies, Inc.'s revenue compounded faster (50.0% CAGR vs -46.5%).

The Comstock Lode is a lode of silver ore located under the eastern slope of Mount Davidson, a peak in the Virginia Range in Virginia City, Nevada, which was the first major discovery of silver ore in the United States and named after Canadian miner Henry Comstock.

Organogenesis Holdings Inc. is a leading regenerative medicine firm specializing in developing and manufacturing advanced therapeutic products for wound care, surgical repair, sports medicine, and dermatology. It serves healthcare providers and patients primarily in the U.S. and select international markets, offering clinically validated solutions for unmet medical needs.

CHCI vs ORGO — Head-to-Head

Bigger by revenue
ORGO
ORGO
1.6× larger
ORGO
$37.2M
$23.9M
CHCI
Growing faster (revenue YoY)
CHCI
CHCI
+98.6% gap
CHCI
41.5%
-57.1%
ORGO
Faster 2-yr revenue CAGR
CHCI
CHCI
Annualised
CHCI
50.0%
-46.5%
ORGO

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
CHCI
CHCI
ORGO
ORGO
Revenue
$23.9M
$37.2M
Net Profit
$13.5M
Gross Margin
35.5%
30.8%
Operating Margin
32.4%
-185.1%
Net Margin
56.3%
Revenue YoY
41.5%
-57.1%
Net Profit YoY
30.5%
EPS (diluted)

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CHCI
CHCI
ORGO
ORGO
Q1 26
$37.2M
Q4 25
$23.9M
$225.6M
Q3 25
$13.3M
$150.9M
Q2 25
$13.0M
$101.0M
Q1 25
$12.6M
$86.7M
Q4 24
$16.9M
$126.7M
Q3 24
$13.0M
$115.2M
Q2 24
$10.8M
$130.2M
Net Profit
CHCI
CHCI
ORGO
ORGO
Q1 26
Q4 25
$13.5M
$43.7M
Q3 25
$541.0K
$21.6M
Q2 25
$1.4M
$-9.4M
Q1 25
$1.6M
$-18.8M
Q4 24
$10.3M
$7.7M
Q3 24
$2.4M
$12.3M
Q2 24
$946.0K
$-17.0M
Gross Margin
CHCI
CHCI
ORGO
ORGO
Q1 26
30.8%
Q4 25
35.5%
Q3 25
11.0%
Q2 25
19.0%
Q1 25
18.6%
72.6%
Q4 24
33.4%
75.5%
Q3 24
26.3%
76.7%
Q2 24
17.2%
77.6%
Operating Margin
CHCI
CHCI
ORGO
ORGO
Q1 26
-185.1%
Q4 25
32.4%
28.1%
Q3 25
5.0%
13.7%
Q2 25
13.7%
-12.5%
Q1 25
13.7%
-30.9%
Q4 24
30.1%
8.1%
Q3 24
21.8%
5.4%
Q2 24
11.4%
-10.7%
Net Margin
CHCI
CHCI
ORGO
ORGO
Q1 26
Q4 25
56.3%
19.4%
Q3 25
4.1%
14.3%
Q2 25
11.1%
-9.3%
Q1 25
12.6%
-21.7%
Q4 24
61.1%
6.1%
Q3 24
18.3%
10.7%
Q2 24
8.8%
-13.1%
EPS (diluted)
CHCI
CHCI
ORGO
ORGO
Q1 26
Q4 25
$0.31
Q3 25
$0.11
Q2 25
$-0.10
Q1 25
$-0.17
Q4 24
$0.05
Q3 24
$0.09
Q2 24
$-0.13

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CHCI
CHCI
ORGO
ORGO
Cash + ST InvestmentsLiquidity on hand
$31.3M
$91.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$70.0M
Total Assets
$85.0M
$520.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CHCI
CHCI
ORGO
ORGO
Q1 26
$91.4M
Q4 25
$31.3M
$93.7M
Q3 25
$26.2M
$63.7M
Q2 25
$30.5M
$73.1M
Q1 25
$28.3M
$110.0M
Q4 24
$28.8M
$135.6M
Q3 24
$21.1M
$94.3M
Q2 24
$17.4M
$89.9M
Total Debt
CHCI
CHCI
ORGO
ORGO
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$62.3M
Q2 24
$63.8M
Stockholders' Equity
CHCI
CHCI
ORGO
ORGO
Q1 26
Q4 25
$70.0M
$300.1M
Q3 25
$56.3M
$255.1M
Q2 25
$55.5M
$233.2M
Q1 25
$53.7M
$242.9M
Q4 24
$52.4M
$262.9M
Q3 24
$41.7M
$278.5M
Q2 24
$39.2M
$263.5M
Total Assets
CHCI
CHCI
ORGO
ORGO
Q1 26
$520.0M
Q4 25
$85.0M
$598.7M
Q3 25
$67.6M
$509.8M
Q2 25
$65.2M
$461.1M
Q1 25
$62.8M
$467.4M
Q4 24
$64.9M
$497.9M
Q3 24
$52.2M
$446.3M
Q2 24
$48.6M
$443.2M
Debt / Equity
CHCI
CHCI
ORGO
ORGO
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.22×
Q2 24
0.24×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CHCI
CHCI
ORGO
ORGO
Operating Cash FlowLast quarter
$4.8M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
0.36×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CHCI
CHCI
ORGO
ORGO
Q1 26
Q4 25
$4.8M
$39.4M
Q3 25
$-3.2M
$3.1M
Q2 25
$2.2M
$-32.9M
Q1 25
$582.0K
$-19.9M
Q4 24
$10.7M
$10.9M
Q3 24
$3.9M
$8.7M
Q2 24
$1.3M
$4.7M
Free Cash Flow
CHCI
CHCI
ORGO
ORGO
Q1 26
Q4 25
$34.8M
Q3 25
$844.0K
Q2 25
$-36.5M
Q1 25
$-23.6M
Q4 24
$7.6M
Q3 24
$6.1M
Q2 24
$2.9M
FCF Margin
CHCI
CHCI
ORGO
ORGO
Q1 26
Q4 25
15.4%
Q3 25
0.6%
Q2 25
-36.1%
Q1 25
-27.2%
Q4 24
6.0%
Q3 24
5.3%
Q2 24
2.2%
Capex Intensity
CHCI
CHCI
ORGO
ORGO
Q1 26
Q4 25
2.1%
Q3 25
1.5%
Q2 25
3.6%
Q1 25
4.2%
Q4 24
2.7%
Q3 24
2.2%
Q2 24
1.4%
Cash Conversion
CHCI
CHCI
ORGO
ORGO
Q1 26
Q4 25
0.36×
0.90×
Q3 25
-5.96×
0.14×
Q2 25
1.51×
Q1 25
0.37×
Q4 24
1.03×
1.43×
Q3 24
1.63×
0.71×
Q2 24
1.35×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CHCI
CHCI

Related Party$22.1M92%
Nonrelated Party$1.9M8%

ORGO
ORGO

Segment breakdown not available.

Related Comparisons